Figure 5.
Infliximab drug survival by adherence status stratified by 4 groups: (1) those late to both infusion 3 (INF3) and INF4, (2) those late to INF3 but on time to INF4, (3) those on time to INF3 but late to INF4, and (4) those on time to both INF3 and INF4.

Infliximab drug survival by adherence status stratified by 4 groups: (1) those late to both infusion 3 (INF3) and INF4, (2) those late to INF3 but on time to INF4, (3) those on time to INF3 but late to INF4, and (4) those on time to both INF3 and INF4.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close